Artiva Biotherapeutics is a San Diego, California–based oncology company with a “manufacturing-first” strategy. They specialize in cell therapy, specifically NK cell therapy targeting cancer. Artiva's portfolio of projects includes their AlloNK platform to advance highly scaled, off-the-shelf, allogeneic NK cell therapies for outpatient administration in the treatment of hematologic cancers and solid tumors, as well as highly active non-genetically modified NK cell and CAR-NK cell therapies. Artiva’s goal is to expand cell therapy so that it can be accessible to patients all over the world.